As biological data volume continues to grow, sequence-based AI is poised to become the dominant discovery layer across pharma, biotech, and industrial biology. Ainnocence is expanding partnerships, ...

The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...

Peer-reviewed discovery platform and data in PNAS show that single transcription factor modulation reverses aging-associated gene expression and restores healthy cellular and tissue function in models ...

TherML™ integrates CombinAbleAI’s advanced, next generation biologics expertise with insitro’s existing small molecule and oligonucleotide capabilities, unifying therapeutic design across all major ...

Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity ...

Ribonucleic acid, or RNA, has emerged as a hot new field after mRNA and miRNA discoveries won Nobel Prizes in 2023 and 2024, respectively, drawing attention to its scientific value and industrial ...

PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship manufacturing facility in Massachusetts. Alnylam plans to spend $250 million in a ...

SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission of RN5681 to the Australian Human ...

The biological world is always expanding as research is constantly being done. Because of this, many findings often fall under the radar despite having the potential to change the world. Here are some ...

Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...